Navigation Links
MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/2/2009

P Pharmaceuticals' first Phase 3 clinical trial of UDB, the company and AstraZeneca are conducting further analyses of the clinical data to determine appropriate next steps for the program. In addition, the company expects to announce clinical results from the efficacy portion of its first Phase 3 clinical trial for MAP0004 during the first half of 2009. At that time the company expects to provide updated financial guidance for 2009.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' expected cash requirements during 2009 described above. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the following: the enrollment, conduct, completion and reporting of clinical
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
2. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
5. Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
6. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
7. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
8. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
9. Endo Pharmaceuticals Appoints William Montague to Board of Directors
10. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... (PRWEB) March 01, 2015 Women’s Excellence ... Obstetric terms on their website. There are over ... all the time. , “This gives our patients a ... use medical terminology that they may not understand. With this ... (which is mobile optimized) and find terms and phrases that they ...
(Date:3/1/2015)... NC (PRWEB) March 01, 2015 Researchers ... reason that so many sheet metal workers contract malignant ... this new report on its website. Click here ... Center for Construction Research and Training monitored 17,345 sheet ... a disproportionate number of them died of mesothelioma ...
(Date:3/1/2015)... Indiana (PRWEB) March 01, 2015 ... statewide Network Service Provider, announces NewWays Networking, LLC ... “By working with IFN, NewWays is well ... meet client’s demand for Internet bandwidth in rural ... , According to Cory Childs IFN Enterprise ...
(Date:3/1/2015)... February 28, 2015 CrossFit Attollo is a ... are offering a special discount to new members. Now ... for a three month contract will receive their fourth month ... would cost members $440. The three month contract is ... and then the fourth month comes in at only $55. ...
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
Breaking Medicine News(10 mins):Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3
... Scientists have identified the receptor in cells of the peripheral ... to sense cold. ,The finding, reported on-line ... the key mechanisms by which the body detects temperature sensation. ... mediates how the body experiences intense stimuli temperature, in ...
... (FDA) today approved Torisel (temsirolimus) for the treatment of a ... carcinoma. Torisel was approved based on a study that ... renal cell carcinoma. The drug is an enzyme inhibitor, a ... ,'We have made significant advances in the battle ...
... is only a pretext for multinational corporations to take control ... in US charge. With sales of over $35 billion ... it takes to buy up pristine springs in some of ... Nestl, which controls one-third of the U.S. market and sells ...
... combined with sulphur to improve its overall strength and durability. ... to reform and reuse old tyres. The only way ... a process that releases heavy metals and other pollutants and ... and colleagues at Swansea University, UK, have shown that spinning ...
... will have a new -- virtually pain free -- ... Health System (SJMHS) announced today it will begin treating ... Wednesday, June 6th. ,This advanced radiosurgery system ... previously inoperable tumors, with astounding accuracy and with little ...
... to emergency needs and low donor turnout. The American Red ... can, to donate blood. ,As of this ... Red Cross had no units of Type O-negative -- the ... below a one-day supply. ,Shortages of Type O-negative ...
Cached Medicine News:Health News:Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh 2Health News:Detecting Cold, Feeling Pain: Study Reveals Why Menthol Fresh 3Health News:FDA: New Drug for Advance Kidney Cancer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2
(Date:3/2/2015)... LOS ANGELES , March 2, 2015 ImmunoCellular Therapeutics, ... report financial results for the year ended December 31, 2014 on ... update conference call and webcast on Thursday, March 12, 2015, at ... Gengos , President and CEO.   , ... international dial-in: (631) 291-4544; conference code 92238648. , , , ...
(Date:3/1/2015)... March 1, 2015  An innovative interventional radiology ... sufferers sustained relief of their headaches, according to ... Interventional Radiology ,s Annual Scientific Meeting . ... University New York Empire State College in Saratoga ... ganglion (SPG) blocks to give patients enough ongoing ...
(Date:2/27/2015)... Pharmaceutical and biotech marketers are often faced ... same indication. This can be a complex balancing act ... of their brands from gaining market share at the ... by benchmarking firm, Best Practices, LLC, 75% of companies ... together as part of a franchise. Marketers have to ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Image-guided treatment shown to break the migraine cycle 2Image-guided treatment shown to break the migraine cycle 3Image-guided treatment shown to break the migraine cycle 4New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2
... Medicine Coalition (PMC) released today the 3rd edition ... Personalized Medicine .  The report documents the growth ... in 2006 to 72 today, and examines opportunities ... medicine as the cost of genetic sequencing declines, ...
... Tandem Diabetes Care, Inc. today announced that the ... clearance to market the t:slim™ Insulin Delivery System (t:slim).  This ... screen, and is the smallest insulin pump system currently available. ... be cleared under the FDA,s new Infusion Pump Improvement Initiative. ...
Cached Medicine Technology:72 Prominent Personalized Medicine Products Available; A Five-Fold Increase in Five Years 2Tandem Diabetes Care Announces FDA Clearance of the t:slim™ Insulin Delivery System 2Tandem Diabetes Care Announces FDA Clearance of the t:slim™ Insulin Delivery System 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: